Table 3.
Detailed results of orthotopic implantation experiments in which colorectal cancer cell lines were inoculated onto the cecal walls of mice using Matrigel
| Cell line | Local tumor formation | Median tumor volume (range) (mm3) | Metastatic tumor formation | ||||
|---|---|---|---|---|---|---|---|
| Cecum B/A (%) | Median tumor weight (range) (g) | LN C/B (%) | Liver D/B (%) | Peritoneum E/B (%) | |||
| KM12c | 7/10 (70) | 0.78 (0.26–1.47) | 480 (417–544) | 7/7 (100) | High LN metastasis group | 0/7 (0) | 0/7 (0) |
| Clone A | 9/9 (100) | 1.47 (0.65–2.14) | 576 (200–1296) | 9/9 (100) | 0/9 (0) | 0/9 (0) | |
| HT‐29 | 18/18 (100) | 0.49 (0.31–0.85) | 180 (80–384) | 17/18 (94) | 2/18 (11) | 0/18 (0) | |
| CX‐1 | 13/13 (100) | 0.56 (0.31–0.72) | 165 (59–416) | 12/13 (92) | 4/13 (31) | 1/13 (8) | |
| LS180 | 12/12 (100) | 1.49 (0.74–8.09) | 925 (136–7142) | 11/12 (92) | 0/12 (0) | 3/12 (25) | |
| MIP101 | 14/15 (93) | 1.53 (0.14–4.95) | 1054 (175–4050) | 12/14 (86) | 0/14 (0) | 7/14 (50) | |
| RKO | 8/8 (100) | 0.85 (0.16–1.79) | 524 (4–1292) | 6/8 (75) | Intermediate LN metastasis group | 0/8 (0) | 0/8 (0) |
| T84 | 8/9 (89) | 0.49 (0.38–0.68) | 141 (63–270) | 6/8 (75) | 1/8 (13) | 0/8 (0) | |
| HCT116 | 14/14 (100) | 1.19 (0.61–3.02) | 704 (352–1521) | 10/14 (71) | 10/14 (71) | 4/14 (29) | |
| LS174T | 7/7 (100) | 1.41 (0.66–2.84) | 800 (306–2450) | 5/7 (71) | 1/7 (14) | 0/7 (0) | |
| WiDr‐TC | 10/10 (100) | 0.87 (0.26–2.76) | 416 (27–1224) | 7/10 (70) | 2/10 (20) | 3/10 (30) | |
| COLO205 | 9/9 (100) | 0.74 (0.54–1.36) | 294 (96–810) | 6/9 (67) | 0/9 (0) | 0/9 (0) | |
| LoVo | 8/8 (100) | 0.70 (0.41–1.81) | 288 (88–1008) | 5/8 (63) | 1/8 (13) | 0/8 (0) | |
| SW480 | 8/8 (100) | 1.08 (0.42–1.27) | 486 (180–1296) | 5/8 (63) | 1/8 (13) | 0/8 (0) | |
| SW48 | 10/10 (100) | 0.60 (0.31–1.47) | 189 (50–650) | 5/10 (50) | 0/10 (0) | 0/10 (0) | |
| COLO320 | 15/15 (100) | 4.13 (0.28–13.6) | 3136 (54–12 500) | 7/15 (47) | 4/15 (27) | 3/15 (20) | |
| HCT‐15 | 9/9 (100) | 1.06 (0.37–1.85) | 448 (50–950) | 3/9 (33) | 1/9 (11) | 1/9 (11) | |
| SW620 | 8/8 (100) | 0.91 (0.62–1.31) | 496 (319–729) | 2/8 (25) | Low LN metastasis group | 1/8 (13) | 0/8 (0) |
| SW1116 | 8/9 (89) | 1.29 (0.52–1.65) | 509 (138–850) | 2/8 (25) | 0/8 (0) | 0/8 (0) | |
| DLD‐1 | 13/17 (76) | 0.41 (0.21–1.43) | 294 (72–850) | 0/13 (0) | 0/13 (0) | 1/13 (8) | |
| HCT‐8 | 9/9 (100) | 0.96 (0.54–1.63) | 607 (245–1224) | 0/9 (0) | 1/9 (11) | 4/9 (44) | |
| SW948 | 11/11 (100) | 1.19 (0.32–5.62) | 544 (64–3613) | 0/11 (0) | 0/11 (0) | 0/11 (0) | |
| Total | 228/238 (96) | NA | NA | 137/228 (60) | 29/228 (13) | 27/228 (12) | |
Twenty‐two of the studied cell lines were divided into three groups, according to the rate of their LN metastasis: high LN metastis group, incidence higher than 80%; intermediate LN metastasis group, 26%≤ 80%; low LN metastasis group, ≤25%. A, the number of mice in which CRC cells were orthotopically implanted, B, the number of mice that successfully formed local tumors in cecum; C, the number of mice with LN metastasis; D, the number of mice with liver metastasis; E, the number of mice with peritoneal dissemination; NA, not applicable.